Coherus BioSciences Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$327.5M
Industry:Biotech
Founded:2010
Lead Investor(s):Healthcare Royalty Partners
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Coherus BioSciences's estimated revenue is currently $22.8M per year.
  • Coherus BioSciences received $75.0M in venture funding in January 2019.
  • Coherus BioSciences's estimated revenue per employee is $82256
  • Coherus BioSciences's total funding is $327.5M.

Employee Data

  • Coherus BioSciences has 277 Employees.
  • Coherus BioSciences grew their employee count by 18% last year.
  • Coherus BioSciences currently has 19 job openings.

Executive Contacts

NameTitle
Juliana ReedVice President Government Affairs
Erik WibergExecutive Vice President, Corporate Development
Richard BoismenuVice President Of Product Development
Joan EggertVice President,Transactions & Legal Affairs
Sarita JainVice President, Business Development
Francie LinDirector, Business Analytics
Jun LiuVice President Operations
Denny LanfearCEO/President/Chairman
Peter WatlerSr Vice President, Process Sciences
Matthew HooperEVP & GENERAL COUNSEL

What Is Coherus BioSciences?

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

277

Number of Employees

$22.8M

Revenue (est)

19

Current Jobs

18%

Employee Growth %

$327.5M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$6.2M4310%N/A
Mission Bio
$10.7M7445%N/A
Rigel Pharmaceu...
$42M2904%N/A
ProTrials Resea...
$26.4M1823%N/A
Trace Genomics
$5.9M4137%N/A
Advanced Cell D...
$25.7M1788%N/A
CellMax Life
$5.7M4011%N/A
Vaxart
$4.2M33-15%N/A
Full Spectrum A...
$6M425%N/A
Calysta
$7.1M49-2%N/A

Coherus BioSciences News

09/03/2019 - Coherus BioSciences Announces New Employment ...

REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective ...

09/08/2019 - Coherus Biosciences (NASDAQ:CHRS) Downgraded by ...

BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a report released on Friday, BidAskClub ...

09/03/2019 - Coherus BioSciences, Inc. (CHRS) Fell By -2.8%, And Here's ...

For its latest trading sesion, Coherus BioSciences, Inc. (CHRS) dropped by -2.8% – here is what that looked like (as of 2019-09-09): ...

Coherus BioSciences Funding

DateAmountRoundLead InvestorsReference
2014-05-20$55.0MCMultipleArticle
2014-11-07$85.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-03-31$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-02$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-02-09$143.8MUndisclosedJ.P. MorganArticle
2019-01-08$75.0MUndisclosedHealthcare Royalty PartnersArticle

Coherus BioSciences Executive Hires

DateNameTitleReference
2014-04-29Michael A. FlemingSVP Commercial StrategyArticle
2014-05-13Lisa M. BellSVP Global Regulatory AffairsArticle
2014-06-10Vince R. AnicettiSVP Global QualityArticle
2016-05-17Patrick O?BrienSVP Investor RelationsArticle
2017-03-28Erik Wibergvp Corporate DevelopmentArticle
2019-01-03Darlene HortonChief Medical and Regulatory Affairs OfficerArticle
2019-03-19Thomas FitzpatrickChief Legal OfficerArticle

Coherus BioSciences Staff Cuts

DateNumber of EmployeesLocationReference
2017-06-2951Article